Generation of dendritic cells ex vivo: Differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors

R. M. Syme, P. Duggan, D. Stewart, S. Glück

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Dendritic cells (DC) are potent antigen-presenting cells that are integral to the initiation of T cell immunity. The ability to culture these cells in vitro has allowed DC immunotherapy to be investigated as a mechanism of enhancing immune responses against various malignancies. We examined the optimal time for generating DC and compared DC generated from normal donors for allogeneic blood stem cell transplantation, or patient's with non-Hodgkin's lymphoma or breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. Experiments were conducted to compare DC cultured prior to and post mobilization chemotherapy. Blood was obtained from consenting patients prior to granulocyte colony-stimulating factor (G-CSF) administration with (non-Hodgkin lymphoma and breast cancer) or without (normal donors) chemotherapy. A sample of apheresis product (AP) was obtained at the time of apheresis. DC were generated from peripheral blood mononuclear cells by culturing the adherent cells in the presence of interleukin-4 and granulocyte-macrophage colony-stimulating factor. Resultant DC were harvested and examined for yield, morphology, phenotype, and function. All cell populations yielded highly pure DC, as assessed by light microscopy and flow cytometry. The average cellular yield was significantly greater from AP than steady-state blood in paired and unpaired samples. Yield did not correlate with the percentage of CD14+ cells, and it negatively correlated with CD34 counts. DC from breast cancer patients functioned significantly better than DC from lymphoma patients in a mixed lymphocyte reaction. These data suggest that the optimal timing of culturing DC is after mobilization, and that differences may exist in the functional capabilities of DC derived from different patient populations.

Original languageEnglish
Pages (from-to)621-630
Number of pages10
JournalJournal of Hematotherapy and Stem Cell Research
Volume10
Issue number5
DOIs
StatePublished - Nov 1 2001
Externally publishedYes

Fingerprint

Dendritic Cells
Lymphoma
Tissue Donors
Breast Neoplasms
Blood Component Removal
Stem Cell Transplantation
Drug Therapy
Non-Hodgkin's Lymphoma
Blood Cells
Mixed Lymphocyte Culture Test
Granulocyte Colony-Stimulating Factor
Antigen-Presenting Cells
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-4
Immunotherapy
Population
Microscopy
Immunity
Flow Cytometry
Cell Culture Techniques

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Generation of dendritic cells ex vivo : Differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors. / Syme, R. M.; Duggan, P.; Stewart, D.; Glück, S.

In: Journal of Hematotherapy and Stem Cell Research, Vol. 10, No. 5, 01.11.2001, p. 621-630.

Research output: Contribution to journalArticle

@article{aba4aa352c7541748b78fa9082e7565c,
title = "Generation of dendritic cells ex vivo: Differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors",
abstract = "Dendritic cells (DC) are potent antigen-presenting cells that are integral to the initiation of T cell immunity. The ability to culture these cells in vitro has allowed DC immunotherapy to be investigated as a mechanism of enhancing immune responses against various malignancies. We examined the optimal time for generating DC and compared DC generated from normal donors for allogeneic blood stem cell transplantation, or patient's with non-Hodgkin's lymphoma or breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. Experiments were conducted to compare DC cultured prior to and post mobilization chemotherapy. Blood was obtained from consenting patients prior to granulocyte colony-stimulating factor (G-CSF) administration with (non-Hodgkin lymphoma and breast cancer) or without (normal donors) chemotherapy. A sample of apheresis product (AP) was obtained at the time of apheresis. DC were generated from peripheral blood mononuclear cells by culturing the adherent cells in the presence of interleukin-4 and granulocyte-macrophage colony-stimulating factor. Resultant DC were harvested and examined for yield, morphology, phenotype, and function. All cell populations yielded highly pure DC, as assessed by light microscopy and flow cytometry. The average cellular yield was significantly greater from AP than steady-state blood in paired and unpaired samples. Yield did not correlate with the percentage of CD14+ cells, and it negatively correlated with CD34 counts. DC from breast cancer patients functioned significantly better than DC from lymphoma patients in a mixed lymphocyte reaction. These data suggest that the optimal timing of culturing DC is after mobilization, and that differences may exist in the functional capabilities of DC derived from different patient populations.",
author = "Syme, {R. M.} and P. Duggan and D. Stewart and S. Gl{\"u}ck",
year = "2001",
month = "11",
day = "1",
doi = "10.1089/152581601753193832",
language = "English",
volume = "10",
pages = "621--630",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Generation of dendritic cells ex vivo

T2 - Differences in steady state versus mobilized blood from patients with breast cancer, with lymphoma, and from normal donors

AU - Syme, R. M.

AU - Duggan, P.

AU - Stewart, D.

AU - Glück, S.

PY - 2001/11/1

Y1 - 2001/11/1

N2 - Dendritic cells (DC) are potent antigen-presenting cells that are integral to the initiation of T cell immunity. The ability to culture these cells in vitro has allowed DC immunotherapy to be investigated as a mechanism of enhancing immune responses against various malignancies. We examined the optimal time for generating DC and compared DC generated from normal donors for allogeneic blood stem cell transplantation, or patient's with non-Hodgkin's lymphoma or breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. Experiments were conducted to compare DC cultured prior to and post mobilization chemotherapy. Blood was obtained from consenting patients prior to granulocyte colony-stimulating factor (G-CSF) administration with (non-Hodgkin lymphoma and breast cancer) or without (normal donors) chemotherapy. A sample of apheresis product (AP) was obtained at the time of apheresis. DC were generated from peripheral blood mononuclear cells by culturing the adherent cells in the presence of interleukin-4 and granulocyte-macrophage colony-stimulating factor. Resultant DC were harvested and examined for yield, morphology, phenotype, and function. All cell populations yielded highly pure DC, as assessed by light microscopy and flow cytometry. The average cellular yield was significantly greater from AP than steady-state blood in paired and unpaired samples. Yield did not correlate with the percentage of CD14+ cells, and it negatively correlated with CD34 counts. DC from breast cancer patients functioned significantly better than DC from lymphoma patients in a mixed lymphocyte reaction. These data suggest that the optimal timing of culturing DC is after mobilization, and that differences may exist in the functional capabilities of DC derived from different patient populations.

AB - Dendritic cells (DC) are potent antigen-presenting cells that are integral to the initiation of T cell immunity. The ability to culture these cells in vitro has allowed DC immunotherapy to be investigated as a mechanism of enhancing immune responses against various malignancies. We examined the optimal time for generating DC and compared DC generated from normal donors for allogeneic blood stem cell transplantation, or patient's with non-Hodgkin's lymphoma or breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. Experiments were conducted to compare DC cultured prior to and post mobilization chemotherapy. Blood was obtained from consenting patients prior to granulocyte colony-stimulating factor (G-CSF) administration with (non-Hodgkin lymphoma and breast cancer) or without (normal donors) chemotherapy. A sample of apheresis product (AP) was obtained at the time of apheresis. DC were generated from peripheral blood mononuclear cells by culturing the adherent cells in the presence of interleukin-4 and granulocyte-macrophage colony-stimulating factor. Resultant DC were harvested and examined for yield, morphology, phenotype, and function. All cell populations yielded highly pure DC, as assessed by light microscopy and flow cytometry. The average cellular yield was significantly greater from AP than steady-state blood in paired and unpaired samples. Yield did not correlate with the percentage of CD14+ cells, and it negatively correlated with CD34 counts. DC from breast cancer patients functioned significantly better than DC from lymphoma patients in a mixed lymphocyte reaction. These data suggest that the optimal timing of culturing DC is after mobilization, and that differences may exist in the functional capabilities of DC derived from different patient populations.

UR - http://www.scopus.com/inward/record.url?scp=0034779752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034779752&partnerID=8YFLogxK

U2 - 10.1089/152581601753193832

DO - 10.1089/152581601753193832

M3 - Article

C2 - 11672508

AN - SCOPUS:0034779752

VL - 10

SP - 621

EP - 630

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 5

ER -